Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean Follmann

Showing results (121-130 of 148) with videos related to

Pageof 15
Sort By:
JAMA Network Open|July 13, 2023
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical TrialsDeborah A Theodore, Angela R Branche, Lily Zhang, et al.
Vaccine|February 23, 2026
Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trialsAaron Hudson, Scott Borgetti, Anne-Marie Rick, et al.
Nature Medicine|December 10, 2021
A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaquesPeng Zhang, Elisabeth Narayanan, Qingbo Liu, et al.
JAMA Network Open|May 28, 2025
Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data: A Secondary Cross-Protocol Analysis of 5 Randomized Clinical TrialsLeah I B Andrews, M Elizabeth Halloran, Kathleen M Neuzil, et al.
The New England Journal of Medicine|December 30, 2020
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineLindsey R Baden, Hana M El Sahly, Brandon Essink, et al.
NPJ Vaccines|April 18, 2026
Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccineHolly Janes, Youyi Fong, Ying Huang, et al.
Vaccine|June 29, 2023
Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trialsChristine B Turley, LaKesha Tables, Trevon Fuller, et al.
The Journal of Infectious Diseases|February 18, 2026
Plasma biomarkers of immunothrombosis are independently associated with death in patients with COVID-19 on ECMOAndrew P Platt, Viviane Callier, Alison Grazioli, et al.
Nature Communications|January 19, 2023
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trialYouyi Fong, Yunda Huang, David Benkeser, et al.
The New England Journal of Medicine|September 22, 2021
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded PhaseHana M El Sahly, Lindsey R Baden, Brandon Essink, et al.
Pageof 15

Showing results (121-130 of 148) with videos related to

Sort By:
Pageof 15
JAMA Network Open|July 13, 2023
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical TrialsDeborah A Theodore, Angela R Branche, Lily Zhang, et al.
Vaccine|February 23, 2026
Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trialsAaron Hudson, Scott Borgetti, Anne-Marie Rick, et al.
Nature Medicine|December 10, 2021
A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaquesPeng Zhang, Elisabeth Narayanan, Qingbo Liu, et al.
JAMA Network Open|May 28, 2025
Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data: A Secondary Cross-Protocol Analysis of 5 Randomized Clinical TrialsLeah I B Andrews, M Elizabeth Halloran, Kathleen M Neuzil, et al.
The New England Journal of Medicine|December 30, 2020
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineLindsey R Baden, Hana M El Sahly, Brandon Essink, et al.
NPJ Vaccines|April 18, 2026
Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccineHolly Janes, Youyi Fong, Ying Huang, et al.
Vaccine|June 29, 2023
Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trialsChristine B Turley, LaKesha Tables, Trevon Fuller, et al.
The Journal of Infectious Diseases|February 18, 2026
Plasma biomarkers of immunothrombosis are independently associated with death in patients with COVID-19 on ECMOAndrew P Platt, Viviane Callier, Alison Grazioli, et al.
Nature Communications|January 19, 2023
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trialYouyi Fong, Yunda Huang, David Benkeser, et al.
The New England Journal of Medicine|September 22, 2021
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded PhaseHana M El Sahly, Lindsey R Baden, Brandon Essink, et al.
Pageof 15